Surveillance of Disease Progression in Metastatic Breast Cancer by Molecular Counting of Circulating Tumor DNA Using Plasma-SeqSensei Breast Cancer in Vitro Diagnostics Assay.

Circulating tumor DNA (ctDNA) quantification surpasses cancer antigen 15 to 3 for metastatic breast cancer surveillance. Clinical translation, however, is limited because of uncertainties about the optimal method and clinically valid ctDNA decision thresholds. Plasma-SeqSensei Breast Cancer IVD kit (PSS) is a novel assay for ctDNA molecular counting, detecting ≥0.

Design of Biodegradable PU Textile Coating.

Polyurethane (PU) coatings are used in diverse applications such as textile coating. Up to today, landfilling is still the most occurring way of processing PU waste. Biodegradation is an alternative route for processing PU waste and decreases the amount of microplastics in the case of landfilling.

Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer.

Cobas EGFR mutation Test v2 was FDA-approved as qualitative liquid biopsy for actionable EGFR variants in non-small cell lung cancer (NSCLC). It generates semiquantitative index (SQI) values that correlate with mutant allele levels, but decision thresholds for clinical use in NSCLC surveillance are lacking. We conducted long-term ctDNA monitoring in 20 subjects with EGFR-mutated NSCLC; resulting in a 155 on-treatment samples.

An artificial intelligence-driven support tool for prediction of urine culture test results.

Background And Aims: We aimed to develop an easily deployable artificial intelligence (AI)-driven model for rapid prediction of urine culture test results.

Material And Methods: We utilized a training dataset (n = 34,584 urine samples) and two separate, unseen test sets (n = 10,083 and 9,289 samples). Various machine learning models were compared for diagnostic performance.